TD Cowen reiterates Olema Pharmaceuticals stock rating on trial outlook

Shares of Olema Pharmaceuticals are down 10% over the past week but up ~190% over six months; InvestingPro notes the stock trades below its Fair Value. TD Cowen reiterated a Buy on OLMA, citing palazestrant’s attractive second- and third-line monotherapy and combination data and expressing confidence in success of Phase III O1/O2 trials; analyst price targets across firms range roughly $38–$60 (Oppenheimer/Stifel at $48). Management change: CFO Shane Kovacs will leave in Jan 2026 with CEO Sean Bohen serving as interim CFO, a governance event investors should monitor.

Analysis

A recent class-level Phase 3 setback has realigned investor focus from single-molecule optimism to trial-design and exposure nuances. For smaller oral SERD/CERAN developers, this raises both a demand-side benefit (faster enrollment as patients re-route into alternative trials) and a supply-side headwind (heightened regulatory scrutiny forcing larger, longer, or biomarker-enriched trials). Expect enrollment velocity to be the fastest early signal: a sustained acceleration over the next 3–9 months materially shortens readout timing and derisks funding profiles for mid-cap players.

Governance and execution risk are perishable near-term catalysts. A CFO transition or similar exec churn typically increases perceived financing risk and option value of downside protection, often widening implied volatility by 20–40% for the incumbent stock in the 3 months around the change. The binary nature of late-stage oncology readouts means a single successful pivotal could drive >2x upside in a patient bid, while a failure can erase a comparable portion of value — position sizing must reflect this asymmetry.

The second-order winners are specialized CDMOs, PK/PD biomarker labs and niche CROs running oral formulation work: their order books can expand quickly if sponsors retool exposure or combination arms. Conversely, players whose business models rely on rapid, low-cost phase 2-to-3 rollups without differentiated exposure could be re-rated lower if regulators demand more robust comparator or survival endpoints. Monitor interim enrollment, biomarker concordance, and any protocol amendments — these are higher-fidelity signals than headline sentiment for sizing exposure over the next 6–18 months.

Key Decisions for Investors

• Long OLMA (2–4% portfolio weight) with a 6–12 month horizon; pair with a 25–40% notional hedge via short XBI (biotech ETF) to neutralize sector beta. Objective: asymmetric upside if pivotal/combo data read as robust; downside capped by hedge to ~30% loss scenario.
• Buy OLMA long-dated call spread (9–15 month expiry) to express binary upside while limiting premium; size at 1–2% portfolio risk. Use spreads to cap max loss; target 2.5x–4x payoff if Phase III primary endpoints are met.
• Protective put strategy: own OLMA equity and buy 3–6 month 20–30% OTM puts to guard against governance/near-term volatility around CFO transition. Cost justified if implied vol > historical vol by 20% – reduces tail risk to single-digit portfolio drawdown.
• Volatility play: if IV spikes >30% on headline noise without new data, sell short-dated strangles against a funded long-dated call position to monetize reversion. Risk: large move on data; cap sizing to 0.5–1% portfolio and set strict buyback triggers.
• Watchboard triggers to scale: +scale in (add 50%) on (a) enrollment milestones met 6–9 months sooner than consensus or (b) positive interim PK/PD biomarker concordance; -scale/exit (trim 50%) on any safety signal or regulatory request for additional primary endpoints. Use these discrete events to manage asymmetric risk/reward.